The objectives of the NWACTU are to perform comprehensive analyses of virologic and immunologic events during HIV infection by systematic patient sampling and detailed laboratory studies in order to evaluate innovative therapies of HIV infection and its complications.
The specific aims are relevant for many patients and reflect the aims of the AACTG.
The aims i nclude the study of novel HIV treatment strategies and agents; the treatment response of HIV in latent reservoirs; the impact of viral and host factors and treatment strategies on long-term and clinical and virologic outcomes; viral dynamic models for evaluating new therapies and guiding treatment strategies; treatment and prophylaxis discontinuation following HIV-treatment induced immune reconstitution; metabolic complications of HIV disease and antiretroviral therapy; the treatment of neuropathy and HIV-associated dementia; the mechanism of immune restoration; the validation of the immunologic determinants of clinical and virologic benefit medicated by therapy; enhancement of restoration of appropriate immune function by application of immune-based therapies; and long-term treatment strategies. The NWACTU is a collaborative effort of three Chicago institutions: Northwestern University Medical School, Rush-Presbyterian-St. Luke's Medical Center, and Cook County Hospital. The ACTU offers several components and capabilities and proposes to use them to make contributions to AIDS research. These components include: a consortium of experienced virologists, clinicians, immunologists, and molecular biologists with complementary areas of expertise; the ability to enroll and retain a large, diverse study population; a history of working together as evidenced by joint publications and investigator-initiated grants; the presence of a quality-controlled laboratory for processing, tracking, and storing specimens; participation in other NIH-directed AIDS research; an organizational plan for administrative, clinical and laboratory endeavors; and the provision of scientific and administrative leadership to the Adult AIDS Clinical Trials Group. These characteristics, and the basic science and clinical capabilities of the group, should allow the NWACTU to support a significant proportion of the specific aims and objectives of the AACTG.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI025915-18S2
Application #
7150401
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Welsch, Sue A
Project Start
1987-09-30
Project End
2007-12-31
Budget Start
2006-01-01
Budget End
2007-12-31
Support Year
18
Fiscal Year
2006
Total Cost
$2,077,986
Indirect Cost
Name
Northwestern University at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Kelesidis, Theodoros; Tran, Thuy Tien T; Stein, James H et al. (2015) Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis 61:651-60
Safren, Steven A; Biello, Katie B; Smeaton, Laura et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One 9:e104178
Sacktor, Ned; Miyahara, Sachiko; Evans, Scott et al. (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620-6
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Safren, Steven A; Hendriksen, Ellen S; Smeaton, Laura et al. (2012) Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS Behav 16:266-77
Sacktor, N; Miyahara, S; Deng, L et al. (2011) Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 77:1135-42
Achenbach, Chad J; Darin, Kristin M; Murphy, Robert L et al. (2011) Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol 6:157-177
Ribaudo, Heather J; Benson, Constance A; Zheng, Yu et al. (2011) No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 52:929-40
Imamichi, Hiromi; Degray, Gerald; Asmuth, David M et al. (2011) HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 25:159-64
Albrecht, Mary; Mukherjee, A Lisa; Tierney, Camlin et al. (2011) A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study. HIV Clin Trials 12:201-14

Showing the most recent 10 out of 87 publications